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The immunological death induction by EY-6 on the human tu-
mor cell lines was screened. Human colon carcinoma 
(HCT15, HCT116), gastric carcinoma (MKN74, SNU668), 
and myeloma (KMS20, KMS26, KMS34) cells were died by 
EY-6 treatment with dose-dependent manner. CRT ex-
pression, a typical marker for the immunological death, was 
increased on the EY-6-treated colorectal and gastric cancer 
cells. Interestingly, the effects on the myeloma cell lines were 
complicated showing cell line dependent differential 
modulation. Cytokine secretion from the EY-6 treated tumor 
cells were dose and cell-dependent. IFN-γ  and IL-12 secre-
tion was increased in the treated cells (200% to over 1000% 
of non-treated control), except HCT116, SNU668 and 
KMS26 cells which their secretion was declined by EY-6. 
Data suggest the potential of EY-6 as a new type of im-
muno-chemotherapeutics inducing tumor-specific cell death. 
Further studies are planned to confirm the efficacy of EY-6 in-
cluding in vivo study. 
[Immune Network 2012;12(2):66-69]
In  the  previous  study  (1),  our  laboratory  defined  the  EY-6 
(a newly synthesized indoledione derivative, methyl 6-oxo-3, 
6-dihydro-2H-naphtho[2,1-b][1,4]thiazine-2-carboxylate)  as  a 
possible  candidate  of  chemotherapeutic  agent  killing  tumor 
cell specifically by inducing  immunological  death in mouse 
colon cancer (MC38 cells in C57BL/6 mouse) model. Data re-
vealed  that  EY-6  could  kill  the  tumor  cell  without  harming 
the  normal  immune  cells.  The  killed-tumor  cells  expressed 
significantly up-regulated calreticulin (CRT), heat-shock pro-
teins (HSPs) on their surface inducing increased DC uptake 
of these cells. Also EY-6 treated tumor cells secreted the IFN-γ 
which may manipulate the tumor-microenvironment favorable 
to eliminate tumor cells. Thus the study was expanded with 
human tumor cell lines to confirm EY-6 as a possible candi-
date as immuo-chemotherapeutics. Human colon carcinoma 
(HCT15, HCT116), gastric carcinoma (MKN74, SNU668), and 
myeloma  (KMS20,  KMS26,  KMS34)  cell  lines  were  treated 
w i t h  E Y - 6  a t  d i f f e r e n t  d o s e s  ( 0 ,  2 5  a n d  5 0  u M )  f o r  2 4 ,  4 8  
and 72 hrs to observe the cytotoxicity by MTT assay. All the 
tumor cells were died by EY-6 with dose-dependent manner. 
However,  differential  intensity  of  cytotoxicity  among  tumor 
cells  was  observed.  Cell  death  was  peaked  on  48  hr  after 
EY-6 incubation. Thus the data from 48 hr incubation with 
EY-6  were  presented  as  representative  cytotoxic  effect  of 
chemicals on the human tumor cells (Fig. 1). It has been not-
ed that the surface expression of CRT or heat-shock proteins 
on the anthracyclines-killed tumor cells leads to the induction 
of tumor-specific immune responses (2-5). Especially, tumor 
cell surface translocation of CRT, a Ca2
＋-binding chaperone 
protein that is located in the lumen of the endoplasmic retic-
ulum (ER), was reported as a representative event defining 
immunological  death  of  tumor  cells.  Translocating  cytosolic 
CRT  onto  the  dead  tumor  cell  surface  functions  as  an 
٘eat-meٙ  signal,  making  the  cell  more  attractive  for  uptake 
by  antigen presenting cell and  thus inducing  tumor-specific 
i m m u n i t y  ( 6 ) .  T r e a t i n g  t u m o r  c e l l s  w i t h  E Y - 6  f o r  4 8  h r  i n-Chemotherapeutic Candidate Inducing Immunological Death of Human Tumor Cell Lines
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Table I. EY-6-induced CRT expression on the tumor cell surface. Cells expressing CRT-FITC on their surface after 48 hr incubation with 
EY-6 was observed by flow cytometry. Alteration of CRT-FITC expression was reported by MFI in each group
EY-6 dosage
Colon cancer Gastric cancer Multiple myeloma
HCT15 HCT116 MKN47 SNU668 KMS20 KMS26 KMS34
0μM (control) 16.0 18.8 15.3 11.9 58.1 12.5 50.1
25μM 36.7 18.2 17.4 12.5 86.5 24.7 48.5
50μM 59.7 30.5 22.2 22.5 57.9 48.6 44.7
Figure 1. Cytotoxicity induced by EY-6 was determined by MTT assay. Human tumor cell lines (colon cancer cells HCT15, HCT116; gastric
cancer cells MKN74, SNU668; and myeloma cells KMS20, KMS26, KMS34) were incubated with different doses (0, 25 and 50μM) of EY-6
for 48 hr at 37
oC. After the incubation, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT solution, 5 mg/ml) was added and
incubated for 4 h at 37
oC. At the end of the incubation, supernatant was removed and the color change induced by dimethyl sulfoxide (DMSO)
was determined at 540 nm with ELISA reader (Molecular Devices, Sunnyvale, CA, USA). The analyzed values were reported as the mean±standard
error. Statistical significance was determined by two-tailed Student’s t-test. Asterisks represented the statistical significance (p＜0.05) compared
to 0μM-control group.
duced the surface expression of CRT most significantly on the 
HCT15, a colon cancer cell and KMS26, a myeloma cell with 
dose-dependent manner (Table I). On the other hand, the ex-
pression of CRT on the HCT116, a colon cancer cell and the 
two gastric cell lines MKN47 and SNU668 was induced only 
with higher concentration (50 uM) of EY-6. Response in mul-
tiple  myeloma  cells  was  interesting  that  without  EY-6  ex-
posure,  two  cell  lines  KMS20  and  KMS34  expressed  CRT 
about 4 times more than all the other tumor cells tested. And 
EY-6 did not affect the CRT expression of these cells (Table 
I). In mouse colon cancer model (1), EY-6 induced the secre-
tion of immune-stimulatory cytokine, IFN-γ from the tumor 
cells.  It  suggested  the  possible  involvement  of  EY-6  in  the 
improvement  of  immune-suppressive  tumor  microenviron-
ment which may allow the tumor immunity induction. Thus, 
the secretion of immune-stimulatory cytokines from the EY-6 
t re at e d h u ma n t u mo r c e lls  wa s o bs er ve d . C yt o k in e  th at  in-
duces the Th1 responses, IL-12 has an important role in an-
ti-tumor  immunity  like  antigen-specific  cytotoxic  T  cell 
induction.  EY-6  exposed  HCT15,  a  colon  cancer  cell,  pro-
duced significant amount of IL-12 (Fig. 2). Same phenomen-
on was detected in MKN74, a gastric cell and KMS20, a mye-
loma cell but with lower level secretion (Fig. 2). However, 
EY-6  dose-dependent  reduction  of  IL-12  secretion  was  also 
observed in tumor cells like HCT116, a colon cancer cell and 
KMS26, a myeloma cell (Fig. 2). IFN-γ secreted into the tu-
mor-microenvironment by infiltrated cells was known to have 
an important role as immune-angiogenic switch (7) which can 
induce the anti-tumor effect. Immunotherapy with IFN-γ se-
creting tumor cells was proven to be effective cancer vaccine 
in  animal  model  (8,9).  However,  in  general,  IFN-γ was 
known to be produced by T cell or NK cell but not by tumor Chemotherapeutic Candidate Inducing Immunological Death of Human Tumor Cell Lines
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Figure 2. EY-6 induced IL-12 secretion from the tumor cells. Culture supernatants from tumor cells incubated with different doses of EY-6 for 
24 hr were obtained to measure the secreted IL-12 by ELISA using commercially available assay kit (eBioscience, SanDiego, CA, USA). The
amount of IL-12 (pg/ml) was reported as the mean±standard error. Statistical significance was determined by two-tailed Student’s t-test. Asterisks
represented the statistical significance (p＜0.05) compared to control group.
Figure 3. EY-6 induced IFN-γ secretion from the tumor cells. Culture supernatants from tumor cells incubated with different doses of EY-6 for 
24 hr were obtained to measure the secreted IFN-γ by ELISA using commercially available assay kit (eBioscience, SanDiego, CA, USA). The
amount of IFN-γ (pg/ml) was reported as the mean±standard error. Statistical significance was determined by two-tailed Student’s t-test. Asterisks
represented the statistical significance (p＜0.05) compared to control group.
cells. Thus to achieve the anti-tumor effect with tumor cell 
vaccine, IFN-γ gene was transfected. However, interestingly 
enough, EY-6 treated mouse colon cancer cells produced a 
significantly elevated amount of IFN-γ (1). This might sug-
gest one of the mechanisms that EY-6 induced the immuno-
logical anti-tumor effect. A significantly elevated IFN-γ secre-
tion  was  observed  in  human  tumor  cells  also,  as  demon-
strated  in  EY-6  treated  HCT15,  a  colon  cancer  cell  and 
MKN74, a gastric cancer cell (Fig. 3). On the other hand, sig-
nificant  reduction  of  IFN-γ secretion  was  observed  in  the 
EY-6 treated SNU668, a gastric cancer cell and in KMS26, a 
myeloma  cell  (Fig.  3).  The  sensitivity  to  the  EY-6  induced 
cytotoxicity correlated with CRT expression and immune-stim-
ulatory cytokine secretion in HCT15 colon cancer cells. Data 
suggest the possibility of EY-6 as a candidate of immuno-che-
motherapeuics for some cancer by which may kill the tumor Chemotherapeutic Candidate Inducing Immunological Death of Human Tumor Cell Lines
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cells directly as well as induce the tumor antigen specific im-
munity  to  evoke  complete  tumor  cell  elimination.  Possible 
mechanisms are increased ٘eat-meٙ signal for DC uptake of 
dead tumor cells by CRT expression and induction of stim-
ulatory cytokine secretion such as IL-12 or IFN-γ, which may 
modulate the tumor microenvironment from immune-suppre-
ssion to immune-induction. However, the EY-6 induced cyto-
toxicity and immune modulatory responses were differential 
among the tested tumor cells. Studies defining the differences 
are  on-going  in  this  laboratory.
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